RCKT
Rocket Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$3.86
+1.85%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +103.2%
- EBIT
- +28.4%
- EPS
- +93.6%
- Free cash flow
- +17.3%
- Operating cash flow
- +16.5%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- +15.1%
- EBIT
- +16.4%
- Net income
- +13.8%
- EPS
- +26.4%
- Free cash flow
- +11.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026